Interim Report January - December 2002

BIOINVENT FINANCIAL STATEMENT 1 JANUARY-31 DECEMBER 2002 q BioInvent is developing drugs against arteriosclerosis and HIV. Acquires rights from prominent research groups in Sweden and the US. q New customers. Three-year agreement with Oxford GlycoSciences (OGS) for development of antibody-based drugs. Other new customers in 2002 include CellControl Laboratories AG and Pharmacia Diagnostics AB. q New agreements for increased cooperation with existing customers. Significant increase in cooperation with GlaxoSmithKline Biologicals, ImmunoGen and Igeneon. q q Net revenue for January - December 2002 increased to SEK 87.1 million (58.3). q Cash flow from current operations and investment activity for January - December 2002: SEK -47.1 million (-74.8). Liquid funds at year end: SEK 343.6 million (338.7). Loss after net financial items for January - December 2002: SEK -46.2 million (-43.5). Contact: Any questions regarding this report will be answered by: Svein Mathisen, President and CEO, +46 (0)46 286 85 67 or Jonas Källmén, CFO, +46 (0)46 286 38 12. The report is also available at www.bioinvent.com BioInvent International AB (publ.) Co. reg. no. 556537-7263 ------------------------------------------------------------ This information was brought to you by Waymaker http://www.waymaker.net The following files are available for download: http://www.waymaker.net/bitonline/2003/09/25/20030925BIT00600/wkr0001.doc The full report http://www.waymaker.net/bitonline/2003/09/25/20030925BIT00600/wkr0002.pdf The full report